|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvedBy
|
1998
|
|
gptkbp:ATCCode
|
N02CC04
|
|
gptkbp:brand
|
gptkb:Maxalt
|
|
gptkbp:CASNumber
|
145202-66-0
|
|
gptkbp:chemicalClass
|
indole derivative
|
|
gptkbp:compatibleWith
|
migraine prevention
cluster headache
|
|
gptkbp:contraindication
|
ischemic heart disease
uncontrolled hypertension
history of stroke
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugInteraction
|
gptkb:MAO_inhibitors
gptkb:SSRIs
gptkb:SNRIs
other triptans
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
Yes
|
|
gptkbp:form
|
gptkb:tablet
orally disintegrating tablet
|
|
gptkbp:hasMolecularFormula
|
C15H19N5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rizatriptan
|
|
gptkbp:IUPACName
|
N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
serotonin 5-HT1B/1D receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
acute migraine attacks
|
|
gptkbp:proteinBinding
|
14%
|
|
gptkbp:PubChem_CID
|
4896
5073
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
dry mouth
sleepiness
|
|
gptkbp:synonym
|
Rizatriptan benzoate
|
|
gptkbp:UNII
|
L6O9Y9Y75Z
|
|
gptkbp:usedFor
|
migraine
|
|
gptkbp:bfsParent
|
gptkb:Triptans
|
|
gptkbp:bfsLayer
|
7
|